Purpose. To discuss the clinical issues we addressed in the development of our institutional guidelines regarding the assessment of iron stores for cancer- and treatment-related anemia and the administration of parenteral iron with erythropoiesis-stimulating agents (ESAs).
Data sources. Studies published from January 1995 to August 2007 were identified by computer searches of Medline and hand searching of bibliographies of the articles identified via the computer searches. The current clinical practice guidelines were identified by computer searches of the web sites for national professional organizations that represent health care professionals who treat patients with cancer.
Results of data analysis. Hematopoietic responses demonstrate that epoetin alfa and darbepoetin alfa provide similar outcomes for patients with chemotherapy-induced anemia (CIA); however, up to 50% of patients receiving these agents fail to adequately respond. Functional iron deficiency defined as a state of iron-restricted erythropoiesis is likely the primary contributor to the lack of response. Hematopoietic responses following ESA therapy with parenteral iron are substantially higher compared to response with no or oral iron.
Conclusions. Iron stores should be assessed in all patients with cancer- or treatment-related anemia and parenteral iron should be administered to patients receiving ESA therapy to improve hematopoietic response. A unique algorithm that summarizes our institutional guidelines to assess iron stores and administer parenteral iron with ESA therapy in patients with CIA is included. J Oncol Pharm Practice (2008) 14: 5—22.
Knight K., Wade S., Balducci L.Prevalence and outcomes of anemia in cancer: a systematic review of the literature . The American Journal of Medicine2004; 116: 11—26.
2.
Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer2004; 40: 2293—306.
3.
National Comprehensive Cancer Network I.Cancer- and treatment-related anemia (3.2007). http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf . Accessed June 19, 2007.
4.
Cella D.Factors influencing quality of life in cancer patients: anemia and fatigue . Semin Oncol1998; 25: 43—6.
5.
Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H.Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer1994 ; 73: 2535—42.
6.
Littlewood TJ , Bajetta E., Nortier JWR, Vercammen E., Rapoport B.Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol2001; 19: 2865—74.
7.
Razzouk BI, Hord JD, Hockenberry M. et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol2006; 24: 3583—9.
8.
Cascinu S., Fedeli A., Del Ferro E., Luzi Fedeli S., Catalano G.Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol1994; 12: 1058—62.
9.
Case Jr DC, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy 10.1093/jnci/85.10.801. J Natl Cancer Inst1993; 85: 801—6.
10.
Henry DH, Brooks Jr BJ, Case Jr DC et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am1995; 1: 252.
11.
Markman M., Reichman B., Hakes T. et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecologic Oncology1993; 49: 172—6.
12.
Birgegard G. , Osterborg A., Hedenus M.Functional iron deficiency effectively overcome by adjuvant IV iron during epoetin treatment. ASH Annual Meeting Abstracts2006; 108: 3725.
13.
Rizzo JD, Somerfield MR, Hagerty KL et al. American Society of Clinical Oncology/American Society of Hematology 2007 clinical practice guideline update on the use of epoetin and darbepoetin . J Clin Oncol2007; Oct 22.
14.
Rizzo JD, Somerfield MR, Hagerty KL et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood2007; Oct 23.
Demetri GDAnaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer2001; 84: 31—7.
18.
Cella D.The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol1997; 34: 13—9.
19.
Cella D., Zagari MJ, Vandoros C., Gagnon DD, Hurtz HJ, Nortier JWEpoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population . J Clin Oncol2003; 21: 366—73.
20.
Fairclough DL, Gagnon DD, Zagari MJ, Marschner N., Dicato M.Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Qual Life Res2003; 12: 1013—27.
21.
Jones M., Schenkel B., Just J., Fallowfield L.Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer2004; 101: 1720—32.
22.
Chang J., Couture F., Young S., McWatters KL, Lau CYWeekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol2005; 23: 2597—605.
23.
Treating anaemia with epoetin alfa is associated with improvements in quality of life in cancer patients receiving chemotherapy. Curr Med Res Opin2005; 21: S9—11.
24.
Epoetin alfa offers clinically significant improvements in the quality of life of anaemic cancer patients. Curr Med Res Opin2005; 21: S12—5.
25.
Bennett CLThe blue cross blue shield assessment technology review: summary of findings . Best Practice & Research Clinical Haematology Erythropoietin Use in Oncology: A Summary of the Evidence2005; 18: 423—31.
26.
Lyman GH, Glaspy J.Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? Cancer2006 ; 106: 223—33.
27.
Boccia R., Malik IA, Raja V. et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist2006; 11: 409—17.
28.
Crawford J. , Cella D., Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer2002; 95: 888—95.
29.
Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial . Lancet2003; 362: 1255—60.
30.
Leyland-Jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol2005; 23: 5960—72.
31.
Food and Drug Administration.Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc and Procrit (epoetin alfa) Ortho Biotech, L.P. for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2_04.pdf. Oncologic Advisory Committee Briefing Document. 2004.
32.
Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol2007; 25: 1027—32.
33.
Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol2002; 20: 4083—107.
34.
Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood2002; 100: 2303—20.
35.
Glaspy J., Vadhan-Raj S., Patel R. et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol2006; 24: 2290—97.
36.
Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist2004; 9: 696—707.
37.
Senecal FM, Yee L., Gabrail N. et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer2005; 6: 446—54.
38.
Waltzman R. , Croot C., Justice GR, Fesen MR, Charu V., Williams D.Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 mcg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist2005; 10: 642—50.
39.
Case AS, Rocconi RP, Kilgore LC, Barnes MNEffectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Gynecol Oncol2006; 101: 499—502.
40.
Glaspy J., Moyo V., Kamin M., Wilhelm FEEarly and standard intervention with epoetin alfa (PROCRIT(R)) 120,000 units (U) every three weeks (Q3W) in patients with cancer receiving chemotherapy — results of a planned interim analysis. ASH Annual Meeting Abstracts2006; 108: 3774.
41.
Shasha D., Dawkins F., Wilhelm FEEpoetin alfa 80,000 U every three weeks (Q3W) in anemic cancer patients (pts) not receiving chemotherapy (CT) or radiation therapy (RT). ASH Annual Meeting Abstracts. 2006; 108: 3755.
42.
Henry D., Kamin M., Wilhelm F., Williams D., Xie J., Woodman R.Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. J Clin Oncol, 2006ASCO Annual Meeting Proceedings Part I. 2006; 24: 8624.
43.
Steensma DP , Molina R., Sloan JA et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. 10.1200/ JCO.2005.02.7276 . J Clin Oncol2006; 24: 1079—89.
44.
Herrington JD, Davidson SL, Tomita DK, Green L., Smith RE, Boccia RVUtilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm2005; 62: 54—62.
45.
Glaspy JA, Jadeja JS, Justice G. et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer2002; 87: 268—76.
46.
Patton J., Reeves T., Wallace J.Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist2004; 9: 451—8.
47.
Vansteenkiste J., Tomita D., Rossi G., Pirker R.Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer2004; 12: 253—62.
48.
Canon JL, Vansteenkiste J., Bodoky G. et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst2006; 98: 273—84.
49.
Kotasek D., Steger G., Faught W. et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer2003; 39: 2026—34.
50.
Hernandez EDJ , Kotasek D., Ganly P., Silberstein P., Tomita D., Lillie T., Boccia R.Effectiveness of darbepoetin alfa 300 mcg every 3 weeks in patients with chemotherapy-induced anemia. Journal of Clinical Oncology, 2006ASCO Annual Meeting Proceedings Part I2006; 24: 18545.
51.
Taylor K., Ganly P., Charu V., et al. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. ASH Annual Meeting Abstracts. November 16, 2005;106: 3556.
52.
Rearden TP, Charu V., Saidman B., Ben-Jacob A., Justice GR, Manaim AS, Tomita D., Rossi, G.Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). J Clin Oncol, 2004ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22: 8064.
53.
Hedenus M., Adriansson M., San Miguel J. et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol2003; 122: 394—403.
54.
Locatelli F. , Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant2004 ; 19: 1—47.
55.
Seidenfeld J., Piper M., Flamm C. et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. 10.1093/jnci/93.16.1204. J Natl Cancer Inst2001; 93: 1204—14.
56.
Granetto C. , Ricci S., Martoni A. et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep2003; 10: 1289—96.
57.
Ineck B., Mason B., Thomas EGAnemia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells B, Posey M. . Pharmacotherapy: a pathophysiologic approach. 6 eds, Stanford: Appleton and Lange; 2004 .
58.
Henry D., Dahl NVIron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy. Community Oncology2007; 4: 95—101.
59.
KDOQI; National Kidney Foundation II.Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis2006; 47: S16—85.
60.
Auerbach M. , Ballard H., Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial . J Clin Oncol2004; 22: 1301—7.
61.
Henry DH, Dahl NV, Auerbach M., Tchekmedyian S., Laufman LRIntravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy . Oncologist2007; 12: 231—42.
62.
Hedenus M., Birgegard G., Nasman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007; 21: 627—32.
63.
Bellet RE, Ghazal H., Flam M., et al. A phase III randomized controlled study comparing iron sucrose intravenously to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology, 2007ASCO Annual Meeting Proceedings Part I. 2007; 25(18S (June 20 Supplement)): 9109.
64.
Lerchenmueller C., Husseini F., Gaede B., Mossman T., Suto T., Vanderbroek A.Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): iron parameters in a randomized controlled trial. ASH Annual Meeting Abstracts2006; 108: 1552.
65.
Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DCEarly prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant2003; 18: 370—7.
66.
Lee EJ, Oh E-J., Park Y-J., Lee HK, Kim BKSoluble transferrin receptor (sTfR), ferritin, and sTfR/log ferritin index in anemic patients with nonhematologic malignancy and chronic inflammation . Clin Chem2002; 48: 1118—21.
67.
Coyne DW, Kapoian T., Suki W. et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron and Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol2007; 18: 975—84.
68.
Haurani FI, Green D., Young K.Iron absorption in hypoferremia. Am J Med Sci1965; 249: 537—47.
69.
Weinstein DA , Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NCInappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease . Blood2002; 100: 3776—81.
70.
Nemeth E., Tuttle MS, Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science2004; 306: 2090—3.
71.
Andrews NCAnemia of inflammation: the cytokinehepcidin link. J Clin Invest2004; 113: 1251—3.
72.
Savonije JH , van Groeningen CJ, van den Broek WJ et al. Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia . Cancer Invest2006; 24: 562—6.
73.
Dexferrum prescribing information. Shirley, NY : American Reagents Laboratories, Inc., 2001.
Venofer prescribing Information. Shirley, NY: American Reagent Laboratories, Inc., 2005.
77.
Weinberg EDThe role of iron in cancer. Eur J Cancer Prev1996; 5: 19—36.
78.
Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran—sensitive and dextran-tolerant patients . Kidney Int2003; 63: 217—24.
79.
McCarthy JT , Regnier CE, Loebertmann CL, Bergstralh EJAdverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. Am J Nephrol2000; 20: 455—62.
80.
Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmen J.On the relative safety of parenteral iron formulations. Nephrol Dial Transplant2004; 19: 1571—5.
81.
Chertow GM, Mason PD, Vaage-Nilsen O., Ahlmen J.Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant2006; 21: 378—82.
82.
Auerbach M. , Chaudhry M., Goldman H., Ballard H.Value of methylprednisolone in prevention of the arthralgiamyalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med1998; 131: 257—60.
83.
Auerbach M. , Henry DHIncreased importance of intravenous iron in chemotherapy-induced anemia. J Clin Oncol2007; 25: 2145—6.
84.
Lalle M., Pistillucci G., Antimi M., D'Aprile M.Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy. J Exp Clin Cancer Res.2005; 24: 197—201.
